| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1244 |
| Trial ID | NCT00285103 |
| Disease | Chronic Lymphocytic Leukemia |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | SPC2996 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia |
| Year | 2005 |
| Country | United States|Denmark|France|United Kingdom |
| Company sponsor | Santaris Pharma A/S |
| Other ID(s) | SPC2996-101 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||